|
Re: Sneaking Suspicion...
|
6
|
Resverlogix Corp.
|
Feb 05, 2021 08:05AM
|
|
Re: Forward looking statements...
|
6
|
Resverlogix Corp.
|
Feb 05, 2021 10:33AM
|
|
Re: IR
|
6
|
Resverlogix Corp.
|
Jan 10, 2023 10:54PM
|
|
Re: Irrational exuberance
|
6
|
Resverlogix Corp.
|
Sep 17, 2020 06:58PM
|
|
Re: Sneaking Suspicion...
|
6
|
Resverlogix Corp.
|
Feb 04, 2021 01:25PM
|
|
Data Safety Monitoring Board Udpate
|
6
|
Resverlogix Corp.
|
Dec 05, 2016 12:21PM
|
|
Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
|
6
|
Resverlogix Corp.
|
Nov 12, 2020 08:05AM
|
|
Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
|
6
|
Resverlogix Corp.
|
Oct 14, 2020 07:35AM
|
|
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
|
6
|
Resverlogix Corp.
|
Jul 10, 2017 07:53AM
|
|
Re: Warning: Long - Thoughts on Management
|
6
|
Resverlogix Corp.
|
Mar 25, 2021 06:36PM
|
|
Re: Latest on COVID-19
|
6
|
Resverlogix Corp.
|
Sep 28, 2022 12:49PM
|
|
Re: Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
|
6
|
Resverlogix Corp.
|
Nov 12, 2020 09:59AM
|
|
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
|
6
|
Resverlogix Corp.
|
Aug 29, 2017 01:03PM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
7
|
Resverlogix Corp.
|
Jun 14, 2020 05:08PM
|
|
Cause for Delay
|
7
|
Resverlogix Corp.
|
Mar 16, 2017 10:45AM
|
|
Re: Merrill Lynch
|
7
|
Resverlogix Corp.
|
Jun 09, 2020 07:44PM
|
|
Re: New to Agoracom
|
7
|
Resverlogix Corp.
|
Dec 30, 2020 03:54PM
|
|
Re: Sarah's reply to my email
|
7
|
Resverlogix Corp.
|
Jan 31, 2019 09:27PM
|
|
Re: The chart set up looks awesome imo....
|
7
|
Resverlogix Corp.
|
Dec 03, 2019 02:53PM
|
|
Re: One week later....
|
7
|
Resverlogix Corp.
|
May 21, 2021 10:05AM
|
